NCT01163721 - Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Ranolazine

Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily

DRUG

Placebo

Placebo to match ranolazine administered orally twice daily

Trial Locations (9)

Rochester Clinical Research (RCR), Rochester

Orlando Clinical Research Center (OCRC), Orlando

SeaView Research Inc., Miami

L-MARC Research Center, Louisville

Midwest Institute For Clinical Research Inc. (MICR), Indianapolis

Vince and Associates Clinical Research, Overland Park

Cetero Research, San Antonio

National Research Institute (NRI), Los Angeles

AMCR Institute, Escondido